EP297: Treating Kids Cholesterol and Testosterone Therapy

Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I’m a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients. Podcast Summary Introduction Dr. Warrick Bishop, a cardiologist, author, and CEO of the Healthy Heart Network, hosts this podcast dedicated to helping people understand cardiovascular health factors like blood pressure, weight, and cholesterol. In this episode, Dr. Bishop discusses two important medical stories: evolving guidelines on cholesterol screening in young people and recent findings on testosterone replacement therapy safety in older men. Key Takeaways: The US Preventative Services Task Force recently recommended against lipid disorder screening in children and people under 20 years old, contrasting with Australian practices that support early intervention in familial hypercholesterolemia cases. Familial hypercholesterolemia is a genetic condition where individuals inherit elevated cholesterol levels; heterozygous males may experience heart attacks as early as 40-50 years old, while homozygous individuals face even earlier cardiac events. Genetic testing in Australia now allows identification of the specific genetic defect in an index case, followed by cascade testing through the family to accurately identify who carries the condition. Early lipid-lowering therapy starting at ages 7-8 years old in genetically confirmed familial hypercholesterolemia cases aims to reduce arterial plaque buildup and extend lifespan. The TRAVERSE study of 5,000 men aged 45-80 found that testosterone replacement therapy showed no increased risk of heart attack, stroke, or prostate cancer over a 33-month follow-up period. Testosterone therapy did show small but statistically significant increases in atrial fibrillation (5.2% vs 3.3%), acute kidney injury (3.5% vs 2.4%), and pulmonary embolism risk. Unexpectedly, testosterone treatment was associated with increased fracture risk, which may be explained by improved quality of life and increased activity levels rather than a direct harmful effect. Testosterone replacement improved sexual function and sense of well-being in treated men, providing benefits that may outweigh the small identified risks for appropriate candidates.